Lead Product(s): GS-248
Therapeutic Area: Dermatology Product Name: GS-248
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Hadean Ventures
Deal Size: $21.1 million Upfront Cash: Undisclosed
Deal Type: Financing July 07, 2020
The investment enables Gesynta to fund continued development of lead candidate GS-248 in systemic sclerosis patients.